Your browser version may not work well with NCBI's Web applications. More information here...
1: J Infect. 1984 Sep;9(2):197-202.Links

Control of epidemic meningococcal meningitis by mass vaccination. II. Persistence of antibody four years after vaccination.

Mohammed I, Onyemelukwe GC, Obineche EN, Gupta N, Oyeyinka GO.

Meningococcal antibody was measured in 928 persons vaccinated with combined groups A and C polysaccharide antigens in Bauchi State, Nigeria between 1979 and 1982. Protective amounts of antibody were detected by the indirect haemagglutination technique up to 4 years after vaccination. This persistence was observed mainly in adults, although a substantial proportion of older children also had persistent antibody. Titres in younger children fell progressively, and by the third year the mean log2 antibody titre was 1.4; this may not confer protection against disease. A rational policy for vaccination against meningococcal meningitis would be to revaccinate younger children after 2 years, older children after 4 years, and adults after 6-8 or more years.

PMID: 6438245 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Meningococcal Vaccine (Menomune® , Menactra® )

    Meningococcal disease is a serious bacterial illness. It is a leading cause of bacterial meningitis in children 2 through 18 years old in the United States.

  • Source: AHFS Consumer Medication Information